SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Three Amigos Stock Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sergio H who wrote (27724)1/2/2002 6:42:45 PM
From: JoeinIowa  Read Replies (1) of 29382
 
CLGY started at a BUY today.

GKM Starts Cellegy Pharmaceuticals (CLGY) at BUY
January 2, 2002 (New York)
Larry Smith, GKM's senior research analyst covering the Pharmaceuticals industry, has today launched coverage of Cellegy Pharmaceuticals (CLGY) with a BUY rating.

From Smith's report : "Cellegy is an emerging specialty pharmaceutical company that should launch its first major drug, Anogesic, in mid-2002, and its second, Tostrex, in early 2003. We think that the anticipated approval of Anogesic in the second quarter of 2002, and the projected launch in the third quarter, will be significant catalysts for the stock. The subsequent projected approval of Tostrex and its introduction in early 2003 will also be important catalysts."

For more information or to receive a copy of the full report, please contact your GKM representative.

Full List of GKM News Items
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News